1、 STINCHCOMBE T E,MIKSAD R A,GOSSAI A,et al.Real-world outcomes for advanced non-small cell lung cancer patients treated with a PD-L1 inhibitor beyond progression[J].Clin Lung Cancer,2020,21(5):389-394.e3. STINCHCOMBE T E,MIKSAD R A,GOSSAI A,et al.Real-world outcomes for advanced non-small cell lung cancer patients treated with a PD-L1 inhibitor beyond progression[J].Clin Lung Cancer,2020,21(5):389-394.e3.
2、 NAJIBI A J,LARKIN K,FENG Z,et al.Chemotherapy dose shapes the expression of immune-interacting markers on cancer cells[J].Cell Mol Bioeng,2022,15(6):535-551. NAJIBI A J,LARKIN K,FENG Z,et al.Chemotherapy dose shapes the expression of immune-interacting markers on cancer cells[J].Cell Mol Bioeng,2022,15(6):535-551.
3、 MERIC-BERNSTAM F,LARKIN J,TABERNERO J,et al.Enhancing anti-tumour efficacy with immunotherapy combinations[J].Lancet,2021,397(10278):1010-1022. MERIC-BERNSTAM F,LARKIN J,TABERNERO J,et al.Enhancing anti-tumour efficacy with immunotherapy combinations[J].Lancet,2021,397(10278):1010-1022.
4、 邓修宁. 化疗联合调强放疗治疗老年(≥65岁)局部晚期鼻咽癌的临床疗效[J].广州医药,2023,54(4):40-44. 邓修宁. 化疗联合调强放疗治疗老年(≥65岁)局部晚期鼻咽癌的临床疗效[J].广州医药,2023,54(4):40-44.
5、 ALVAREZ ARIAS D A,KIM H J,ZHOU P,et al.Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity[J].Cancer Immunol Res,2014,2(3):207-216. ALVAREZ ARIAS D A,KIM H J,ZHOU P,et al.Disruption of CD8+ Treg activity results in expansion of T follicular helper cells and enhanced antitumor immunity[J].Cancer Immunol Res,2014,2(3):207-216.
6、 GUBIN M M,ZHANG X,SCHUSTER H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581. GUBIN M M,ZHANG X,SCHUSTER H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581.
7、 MOTZ G T,COUKOS G.Deciphering and reversing tumor immune suppression[J].Immunity,2013,39(1):61-73. MOTZ G T,COUKOS G.Deciphering and reversing tumor immune suppression[J].Immunity,2013,39(1):61-73.
8、 TAO Z Y,WANG L,ZHU W Y,et al.Lingual denervation improves the efficacy of anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling[J].Cancer Res Commun,2024,4(2):418-430. TAO Z Y,WANG L,ZHU W Y,et al.Lingual denervation improves the efficacy of anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGFβ signaling[J].Cancer Res Commun,2024,4(2):418-430.
9、 XIE P,YU M,ZHANG B,et al.CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma[J].J Hepatol,2024, 81(1):93-107. XIE P,YU M,ZHANG B,et al.CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma[J].J Hepatol,2024, 81(1):93-107.
10、 WU W J,LIU Q,AN P G,et al.Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma:A real-world retrospective study[J].Front Immunol,2023(14):1282629. WU W J,LIU Q,AN P G,et al.Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma:A real-world retrospective study[J].Front Immunol,2023(14):1282629.
11、 IKEDA G,MIYAKOSHI J,YAMAMOTO S,et al.Nivolumab in unresectable advanced,recurrent or metastatic esophageal squamous cell carcinoma[J].Future Oncol,2024,20(11):665-677. IKEDA G,MIYAKOSHI J,YAMAMOTO S,et al.Nivolumab in unresectable advanced,recurrent or metastatic esophageal squamous cell carcinoma[J].Future Oncol,2024,20(11):665-677.
12、 HUI R,LIU X,FAN Z,et al.The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma[J].J Cancer,2024,15(6):1668-1674. HUI R,LIU X,FAN Z,et al.The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma[J].J Cancer,2024,15(6):1668-1674.
13、 CHEN C,HUANG F,LI X,et al.Identification of splicing factors signature predicting prognosis risk and the mechanistic roles of novel oncogenes in HNSCC[J].Biochim Biophys Acta Mol Basis Dis,2024,1870(4):167115. CHEN C,HUANG F,LI X,et al.Identification of splicing factors signature predicting prognosis risk and the mechanistic roles of novel oncogenes in HNSCC[J].Biochim Biophys Acta Mol Basis Dis,2024,1870(4):167115.
14、 STUART T,BUTLER A,HOFFMAN P,et al.Comprehensive integration of single-cell data[J].Cell,2019,177(7):1888-1902.e21. STUART T,BUTLER A,HOFFMAN P,et al.Comprehensive integration of single-cell data[J].Cell,2019,177(7):1888-1902.e21.
15、 H?NZELMANN S,CASTELO R,GUINNEY J.GSVA:Gene set variation analysis for microarray and RNA-seq data[J].BMC Bioinformatics,2013(14):7. H?NZELMANN S,CASTELO R,GUINNEY J.GSVA:Gene set variation analysis for microarray and RNA-seq data[J].BMC Bioinformatics,2013(14):7.
16、 KANEHISA M.Toward understanding the origin and evolution of cellular organisms[J].Protein Sci,2019,28(11):1947-1951. KANEHISA M.Toward understanding the origin and evolution of cellular organisms[J].Protein Sci,2019,28(11):1947-1951.
17、 KANEHISA M,FURUMICHI M,SATO Y,et al.KEGG: Integrating viruses and cellular organisms[J].Nucleic Acids Res,2021,49(D1):D545-D551. KANEHISA M,FURUMICHI M,SATO Y,et al.KEGG: Integrating viruses and cellular organisms[J].Nucleic Acids Res,2021,49(D1):D545-D551.
18、 CHANDRASHEKAR D S,KARTHIKEYAN S K,KORLA P K,et al.UALCAN: An update to the integrated cancer data analysis platform[J].Neoplasia,2022(25):18-27. CHANDRASHEKAR D S,KARTHIKEYAN S K,KORLA P K,et al.UALCAN: An update to the integrated cancer data analysis platform[J].Neoplasia,2022(25):18-27.
19、 LI C,GUAN R,LI W,et al.Single-cell RNA sequencing reveals tumor immune microenvironment in human hypopharygeal squamous cell carcinoma and lymphatic metastasis[J].Front Immunol,2023(14):1168191. LI C,GUAN R,LI W,et al.Single-cell RNA sequencing reveals tumor immune microenvironment in human hypopharygeal squamous cell carcinoma and lymphatic metastasis[J].Front Immunol,2023(14):1168191.
20、 GOLDMAN M J,CRAFT B,HASTIE M,et al.Visualizing and interpreting cancer genomics data via the Xena platform[J].Nat Biotechnol,2020,38(6):675-678. GOLDMAN M J,CRAFT B,HASTIE M,et al.Visualizing and interpreting cancer genomics data via the Xena platform[J].Nat Biotechnol,2020,38(6):675-678.
21、 VINAY D S,RYAN E P,PAWELEC G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[J].Semin Cancer Biol,2015,35(Suppl):S185-S198. VINAY D S,RYAN E P,PAWELEC G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[J].Semin Cancer Biol,2015,35(Suppl):S185-S198.
22、 WANG Z,LI B,LI S,et al.Metabolic control of CD47 expression through lat2-mediated amino acid uptake promotes tumor immune evasion[J].Nat commun,2022,13(1):6308. WANG Z,LI B,LI S,et al.Metabolic control of CD47 expression through lat2-mediated amino acid uptake promotes tumor immune evasion[J].Nat commun,2022,13(1):6308.
23、 ZAGHI E,CALVI M,MARCENARO E,et al.Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy[J].J Leukoc Biol,2019,105(6):1243-1251. ZAGHI E,CALVI M,MARCENARO E,et al.Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy[J].J Leukoc Biol,2019,105(6):1243-1251.
24、 van MONTFOORT N,BORST L,KORRER M J,et al.NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines[J].Cell,2018,175(7):1744-1755.e15. van MONTFOORT N,BORST L,KORRER M J,et al.NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines[J].Cell,2018,175(7):1744-1755.e15.
25、 ANDRé P,DENIS C,SOULAS C,et al.Anti-NKG2A mab is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells [J].Cell,2018,175(7):1731-1743.e13. ANDRé P,DENIS C,SOULAS C,et al.Anti-NKG2A mab is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells [J].Cell,2018,175(7):1731-1743.e13.
26、 BHATIA A,BURTNESS B.Treating head and neck cancer in the age of immunotherapy:A 2023 update[J].Drugs,2023,83(3):217-248. BHATIA A,BURTNESS B.Treating head and neck cancer in the age of immunotherapy:A 2023 update[J].Drugs,2023,83(3):217-248.
27、 ARGIRIS A,KARAMOUZIS M V,RABEN D,et al.Head and neck cancer[J].Lancet,2008,371(9625):1695-1709. ARGIRIS A,KARAMOUZIS M V,RABEN D,et al.Head and neck cancer[J].Lancet,2008,371(9625):1695-1709.
28、 邬要芬,冯燕英,幸敏清,等.多维化整体护理模式对头颈部恶性肿瘤患者放射性口腔黏膜炎的影响[J].现代医院,2023,23(7):1145-1148. 邬要芬,冯燕英,幸敏清,等.多维化整体护理模式对头颈部恶性肿瘤患者放射性口腔黏膜炎的影响[J].现代医院,2023,23(7):1145-1148.
29、 SIEGEL REBECCA L,MILLER KIMBERLY D,JEMAL AHMEDIN.Cancer statistics,2018[J].CA:A cancer journal for clinicians,2018,68(1):7-30. SIEGEL REBECCA L,MILLER KIMBERLY D,JEMAL AHMEDIN.Cancer statistics,2018[J].CA:A cancer journal for clinicians,2018,68(1):7-30.
